Bladder drainage using the coreflow prostatic stent after REZUM therapy

To evaluate the feasibility and short-term outcomes of postoperative bladder drainage using a temporary prostatic urethral stent following Rezūm™ therapy.

This prospective bicentric pilot study included 32 consecutive patients undergoing Rezūm™ therapy between March 2025 and February 2026. Postoperative bladder drainage was performed using a temporary prostatic stent (CoreFlow™, ProstaLund AB, Sweden). The primary endpoint was overall strategy success, defined as successful device insertion, maintenance until planned removal without conversion to standard urethral catheterisation, and no secondary re-catheterisation.

Overall strategy success was achieved in 26 of 32 patients (81%). CoreFlow™ stent insertion was successful in 29 patients (91%). Median duration of stenting was 4 days (IQR 4-6). At 30 days after device removal, median patient satisfaction was 8 (IQR 7-9), and median discomfort score was 2 (IQR 1-2). Macroscopic haematuria occurred in 15 patients (47%), urinary retention in 3 (9%), and urinary tract infection in 1 (3%). No device migration or unplanned hospitalisation was observed.

Temporary prostatic stenting appears to be a feasible and well-tolerated postoperative drainage strategy following Rezūm™ therapy. Larger comparative studies are needed to determine its clinical benefit.